Time interval to conversion of interferon-γ release assay after exposure to tuberculosis

European Respiratory Journal

Volumn 37, Issue 6, 2011, Pages 1447-1452

  Lee, S W ^a,b   Oh, D K ^a   Lee, S H ^b   Kang, H Y ^b   Lee, C T ^a   Yim, J J ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Contacts; Infection control; Interferon assay; Serial testing; Tuberculosis

Indexed keywords

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA FINGERPRINTING; EPIDEMIC; EXPOSURE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SOLDIER; SOUTH KOREA; TUBERCULIN TEST;

HUMANS; IMMUNOLOGIC TESTS; INCIDENCE; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MILITARY PERSONNEL; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; SMOKING; TIME FACTORS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 79958012592     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00089510     Document Type: Article

References (25)

1. World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing: WHO Report 2009. Report No. WHO/HTM/TB/2009.411. Geneva, World Health Organization, 2009.
2. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J 2002; 19: 765-775. (Pubitemid 34285174)
3. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-1866. (Pubitemid 35417778)
4. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756-2761.
5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
6. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. Clinical Guideline 33. London, National Institute for Health and Clinical Excellence, 2006.
7. Mazurek M, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacteriumtuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
8. Wasz-Hockert O. On the period of incubation in tuberculosis. Ann Med Intern Fenn 1947; 96: 764-772.
9. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
10. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-975. (Pubitemid 23358739)
11. Kim HJ, Oh SY, Lee JB, et al. Tuberculin survey to estimate the prevalence of tuberculosis infection of the elementary schoolchildren under high BCG vaccination coverage. Tuberc Respir Dis 2008; 65: 269-276.
12. Choi CM, Kang CI, Kim DH, et al. The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea. Int J Tuberc Lung Dis 2006; 10: 1342-1346.
13. Lee SW, Jang YS, Park CM, et al. The role of chest CT scanning in TB outbreak investigation. Chest 2010; 137: 1057-1064.
14. Lew WJ, Jung YJ, Song JW, et al. Combined use of QuantiFERON®-TB Gold assay and chest computed tomography in a tuberculosis outbreak. Int J Tuberc Lung Dis 2009; 13: 633-639.
15. Cellestis, Inc. QuantiFERON®-TB Gold (In-Tube Method) Package Insert. Valencia, CA, Cellestis, Inc., 2006. www.cellestis.com/IRM/Content/pdf/ QuantiFeron%20US%20VerH-Jul2010.pdf Date last updated: July 2010. Date last accessed: October 7, 2010.
16. World Health Organization. Laboratory Services in Tuberculosis Control. Geneva, World Health Organization, 1998.
17. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. 3rd Edn. Geneva, World Health Organization, 2003.
18. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000; 55: 887-901.
19. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409. (Pubitemid 23028649)
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174. (Pubitemid 8054849)
21. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-γ responses at 6 weeks following tuberculin skin testing. Eur Respir J 2007; 29: 1282-1283.
22. Igari H, Watanabe A, Sato T. Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection. Int J Tuberc Lung Dis 2007; 11: 788-791. (Pubitemid 47056989)
23. Vilaplana C, Ruiz-Manzano J, Gil O, et al. The tuberculin skin test increases the responses measured by T cell interferon-γ release assays. Scand J Immunol 2008; 67: 610-617. (Pubitemid 351677412)
24. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-γ responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180: 49-58.
25. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 2006; 174: 349-355. (Pubitemid 44156616)